BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34975332)

  • 1. Verdinexor, a Selective Inhibitor of Nuclear Exportin 1, Inhibits the Proliferation and Migration of Esophageal Cancer via XPO1/c-Myc/FOSL1 Axis.
    Ou L; Wang X; Cheng S; Zhang M; Cui R; Hu C; Liu S; Tang Q; Peng Y; Chai R; Xie S; Wang S; Huang W; Wang X
    Int J Biol Sci; 2022; 18(1):276-291. PubMed ID: 34975332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor.
    Pan L; Cheng C; Duan P; Chen K; Wu Y; Wu Z
    J Exp Clin Cancer Res; 2021 Aug; 40(1):255. PubMed ID: 34384466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication
    Jorquera PA; Mathew C; Pickens J; Williams C; Luczo JM; Tamir S; Ghildyal R; Tripp RA
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30541831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro toxicity and efficacy of verdinexor, an exportin 1 inhibitor, on opportunistic viruses affecting immunocompromised individuals.
    Widman DG; Gornisiewicz S; Shacham S; Tamir S
    PLoS One; 2018; 13(10):e0200043. PubMed ID: 30332435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
    Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo.
    Perwitasari O; Johnson S; Yan X; Howerth E; Shacham S; Landesman Y; Baloglu E; McCauley D; Tamir S; Tompkins SM; Tripp RA
    J Virol; 2014 Sep; 88(17):10228-43. PubMed ID: 24965445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
    Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The selective inhibitor of nuclear export (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines.
    Breitbach JT; Louke DS; Tobin SJ; Watts MR; Davies AE; Fenger JM
    Vet Comp Oncol; 2021 Jun; 19(2):362-373. PubMed ID: 33438820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.
    Breit MN; Kisseberth WC; Bear MD; Landesman Y; Kashyap T; McCauley D; Kauffman MG; Shacham S; London CA
    BMC Vet Res; 2014 Jul; 10():160. PubMed ID: 25022346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.
    Conforti F; Zhang X; Rao G; De Pas T; Yonemori Y; Rodriguez JA; McCutcheon JN; Rahhal R; Alberobello AT; Wang Y; Zhang YW; Guha U; Giaccone G
    Cancer Res; 2017 Oct; 77(20):5614-5627. PubMed ID: 28819023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.
    Wang J; Sun T; Meng Z; Wang L; Li M; Chen J; Qin T; Yu J; Zhang M; Bie Z; Dong Z; Jiang X; Lin L; Zhang C; Liu Z; Jiang R; Yang G; Li L; Zhang Y; Huang D
    Cancer Lett; 2021 Apr; 503():197-212. PubMed ID: 33493586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
    Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C
    J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
    Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
    Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.
    Schmidt J; Braggio E; Kortuem KM; Egan JB; Zhu YX; Xin CS; Tiedemann RE; Palmer SE; Garbitt VM; McCauley D; Kauffman M; Shacham S; Chesi M; Bergsagel PL; Stewart AK
    Leukemia; 2013 Dec; 27(12):2357-65. PubMed ID: 23752175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.
    Tabe Y; Kojima K; Yamamoto S; Sekihara K; Matsushita H; Davis RE; Wang Z; Ma W; Ishizawa J; Kazuno S; Kauffman M; Shacham S; Fujimura T; Ueno T; Miida T; Andreeff M
    PLoS One; 2015; 10(9):e0137210. PubMed ID: 26340096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.
    Azmi AS; Muqbil I; Wu J; Aboukameel A; Senapedis W; Baloglu E; Bollig-Fischer A; Dyson G; Kauffman M; Landesman Y; Shacham S; Philip PA; Mohammad RM
    Sci Rep; 2015 Nov; 5():16077. PubMed ID: 26536918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway.
    Zhao C; Yang ZY; Zhang J; Li O; Liu SL; Cai C; Shu YJ; Pan LJ; Gong W; Dong P
    J Transl Med; 2022 Sep; 20(1):434. PubMed ID: 36180918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of XPO1 Overexpression with NF-κB and Ki67 in Colorectal Cancer.
    Aladhraei M; Kassem Al-Thobhani A; Poungvarin N; Suwannalert P
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3747-3754. PubMed ID: 31870117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.
    Pickens JA; Tripp RA
    Viruses; 2018 Jan; 10(1):. PubMed ID: 29361733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
    De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
    Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.